ALPCO + GeneProof Merge to Form a Global Diagnostics Company
In April of this year, ALPCO proudly announced its merger with GeneProof. Together we are a global leader in immunodiagnostics and molecular diagnostics providing you, our customers, with reagents and proprietary automated sample-to-answer solutions for the tests that matter most to you. Through the depth and breadth of our respective portfolios, ALPCO and GeneProof provide you with the opportunity to choose the methods and tests that align with your mission.
What solutions does GeneProof bring to the table?
GeneProof’s portfolio is primarily focused on infectious and genetic diseases. With a strong emphasis on quality, GeneProof offers technologically advanced real-time PCR kits and user-friendly automated instrument platforms for both nucleic acid extraction and walkaway sample-to-answer testing that meet the diverse throughput needs of laboratories.
What does this mean for you?
A Global Diagnostic Company. Accuracy and Efficiency. Together. Our walk-away sample-to-answer testing solutions include:
- Molecular Diagnostics Assays & Instrumentation: Targeted or panel-based PCR testing for Immunocompromised/Transplant, Sexually Transmitted Infections, and Thrombotic Mutations.
- Flash Chemiluminescence Immunoassays & Instrumentation: Protein biomarker testing for Gastroenterology
- Multiplex Allergy Assays & Instrumentation: Immunoassay testing for total and specific IgE
- Multiplex Chemiluminescence Immunoassays & Instrumentation: Panel-based protein biomarker testing for Gastroenterology
- Plate-based Immunoassays & Instrumentation: ELISA’s for the detection of biomarkers within Diabetes & Obesity, Sleep, and Complement